Iranian vaccine against Omicron concludes effective clinical trials

Tehran, Feb 17 (Prensa Latina) An Iranian pharmaceutical company has concluded the clinical trials in animals of a vaccine against the Omicron SARS-CoV-2 variant with 100 percent effectiveness, a health communique reported on Thursday.

February 17, 2022
06:58

The announcement of the new vaccine, focused on the highly contagious Covid-19 variant, was made by Iran’s Shifa Pharmed Industrial Group, which has produced the home-grown COVIran Barekat vaccine against the coronavirus, the first immunizer in Iran to fight Covid-19.

Shifa Pharmed also announced the presentation of the protocol to the Iranian Food and Drug Administration, in order to obtain the necessary permits.

Iran currently has more than 80 percent of its population fully vaccinated, enabling it to deal more effectively with the sixth wave of contagions, which is being driven by Omicron.

The country announced its first vaccine in June 2021 and shortly thereafter, it added the Soberana 02 vaccine, jointly developed by Iran and Cuba.

pgh/iff/jf/ynr